786 related articles for article (PubMed ID: 19074086)
1. The pathophysiology of ITP revisited: ineffective thrombopoiesis and the emerging role of thrombopoietin receptor agonists in the management of chronic immune thrombocytopenic purpura.
Gernsheimer TB
Hematology Am Soc Hematol Educ Program; 2008; ():219-26. PubMed ID: 19074086
[TBL] [Abstract][Full Text] [Related]
2. New drugs for familiar therapeutic targets: thrombopoietin receptor agonists and immune thrombocytopenic purpura.
Kuter DJ
Eur J Haematol Suppl; 2008 Feb; (69):9-18. PubMed ID: 18211568
[TBL] [Abstract][Full Text] [Related]
3. Epidemiology and pathophysiology of immune thrombocytopenic purpura.
Gernsheimer T
Eur J Haematol Suppl; 2008 Feb; (69):3-8. PubMed ID: 18211567
[TBL] [Abstract][Full Text] [Related]
4. Pathophysiology and management of primary immune thrombocytopenia.
Kashiwagi H; Tomiyama Y
Int J Hematol; 2013 Jul; 98(1):24-33. PubMed ID: 23702914
[TBL] [Abstract][Full Text] [Related]
5. Romiplostim in chronic immune thrombocytopenic purpura.
Cersosimo RJ
Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
[TBL] [Abstract][Full Text] [Related]
6. The pathogenesis of chronic immune thrombocytopenic purpura.
McMillan R
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S3-S11. PubMed ID: 18096470
[TBL] [Abstract][Full Text] [Related]
7. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
8. Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management.
Stasi R; Evangelista ML; Stipa E; Buccisano F; Venditti A; Amadori S
Thromb Haemost; 2008 Jan; 99(1):4-13. PubMed ID: 18217129
[TBL] [Abstract][Full Text] [Related]
9. Pathophysiology and management of chronic immune thrombocytopenia: focusing on what matters.
Toltl LJ; Arnold DM
Br J Haematol; 2011 Jan; 152(1):52-60. PubMed ID: 21083652
[TBL] [Abstract][Full Text] [Related]
10. Review article: second-generation thrombopoietin agents for treatment of chronic idiopathic thrombocytopenic purpura in adults.
Lam MS
J Oncol Pharm Pract; 2010 Jun; 16(2):89-103. PubMed ID: 19525300
[TBL] [Abstract][Full Text] [Related]
11. Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.
Makar RS; Zhukov OS; Sahud MA; Kuter DJ
Am J Hematol; 2013 Dec; 88(12):1041-4. PubMed ID: 23913253
[TBL] [Abstract][Full Text] [Related]
12. Current Management of Primary Immune Thrombocytopenia.
Provan D; Newland AC
Adv Ther; 2015 Oct; 32(10):875-87. PubMed ID: 26499177
[TBL] [Abstract][Full Text] [Related]
13. Emerging strategies to treat chronic immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
[TBL] [Abstract][Full Text] [Related]
14. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia.
Alvarez Román MT; Fernández Bello I; Arias-Salgado EG; Rivas Pollmar MI; Jiménez Yuste V; Martín Salces M; Butta NV
Thromb Haemost; 2014 Jul; 112(1):65-72. PubMed ID: 24500066
[TBL] [Abstract][Full Text] [Related]
15. Thrombopoietin receptor agonist (TPO-RA) treatment raises platelet counts and reduces anti-platelet antibody levels in mice with immune thrombocytopenia (ITP).
Kapur R; Aslam R; Speck ER; Rebetz JM; Semple JW
Platelets; 2020; 31(3):399-402. PubMed ID: 31146647
[TBL] [Abstract][Full Text] [Related]
16. Milestones in understanding platelet production: a historical overview.
Kuter DJ
Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
[TBL] [Abstract][Full Text] [Related]
17. Regulation of serum thrombopoietin levels by platelets and megakaryocytes in patients with aplastic anaemia and idiopathic thrombocytopenic purpura.
Ichikawa N; Ishida F; Shimodaira S; Tahara T; Kato T; Kitano K
Thromb Haemost; 1996 Aug; 76(2):156-60. PubMed ID: 8865522
[TBL] [Abstract][Full Text] [Related]
18. Pathophysiology of Autoimmune Thrombocytopenia: Current Insight with a Focus on Thrombopoiesis.
Marini I; Bakchoul T
Hamostaseologie; 2019 Aug; 39(3):227-237. PubMed ID: 30802916
[TBL] [Abstract][Full Text] [Related]
19. Advances in megakaryocytopoiesis and thrombopoiesis: from bench to bedside.
Deutsch VR; Tomer A
Br J Haematol; 2013 Jun; 161(6):778-93. PubMed ID: 23594368
[TBL] [Abstract][Full Text] [Related]
20. Eltrombopag: an update on the novel, non-peptide thrombopoietin receptor agonist for the treatment of immune thrombocytopenia.
Kühne T; Imbach P
Ann Hematol; 2010 Jul; 89 Suppl 1():67-74. PubMed ID: 20405290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
